In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...
Jan. 6, 2006 — The US Food and Drug Administration (FDA) approved in 2005 a rapid point-of-care test for adenovirus in tear fluid as an aid in the differential diagnosis of acute conjunctivitis; a new ...
San Francisco, CA - Measurement of serum amino terminal fragment of prohormone brain-type natriuretic peptide (NT-proBNP) can add useful information to the standard risk assessment of people with ...
Measuring N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels preoperatively among patients scheduled to undergo inpatient noncardiac surgery can strongly predict the risk of major cardiac ...
A simple blood test for the protein NT-proBNP accurately predicts the risk of heart attack, heart failure, stroke and death in patients with known cardiovascular disease, according to a study led by a ...
The diagnostic potential of N-terminal pro-B-type natriuretic peptide (NT-proBNP) testing in patients with suspected heart failure (HF) has been demonstrated, but whether this test reduces costs and ...
NT-proBNP testing should become compulsory for referring patients to specialist heart failure services to improve diagnosis of the condition in primary care, an expert report has said. The Alliance ...
The LumiraDx NT-proBNP and the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test. Run on the highly portable LumiraDx Platform, they are ...
Mumbai: Roche Diagnostics India announces the launch of its point-of-care (PoC) NT-proBNP test for screening diabetes patients who are at risk of cardiovascular diseases (CVD) such as heart failure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results